Approval · Notice of Compliance 26077 · 2021
RETEVMO: Notice of Compliance 26077
Issued June 15, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 26077
- Date
- June 15, 2021
- Company
- Loxo Oncology Inc
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- With conditions
- Yes (NOC/c)
Products in this notice
Medicinal ingredients
- SELPERCATINIB 40 MG per CAP
- SELPERCATINIB 80 MG per CAP